Why it matters
The pharmaceuticals context.
Post-pandemic supply-chain pressure and bipartisan concern about US reliance on overseas active-pharmaceutical-ingredient (API) production drove an unprecedented wave of domestic pharmaceutical capacity announcements beginning in 2023. Eli Lilly, Novo Nordisk, and Johnson & Johnson lead capacity commitments that exceed any peer's investment in the prior two decades, much of it tied to GLP-1, oncology, and biologics demand.
Project record
At a glance
- Company
- Novo Nordisk
- Industry
- Pharmaceuticals
- Location
- Clayton, North Carolina
- Investment
- $4.10B
- Expected jobs
- 1,000
- Status
- Under Construction
- Announced
- Jun 24, 2024
- Expected opening
- Jan 1, 2027
- Added to tracker
- Apr 15, 2025
Sources
Official references
- Primary source https://www.novonordisk.com/news-and-media.html
Related
Other projects to know
In North Carolina
Back to the tracker/projects/novo-nordisk-clayton